LYT-500 / PureTech - LARVOL DELTA

PureTech Announces Annual Results for Year Ended December 31, 2021 (Businesswire) - "In the 2022 post-period, we nominated a new therapeutic candidate, LYT-510...We intend to file for regulatory approval to initiate first-in-human studies at year end 2022 and initiate a clinical study evaluating LYT-510 as a single agent for the potential treatment of IBD and chronic pouchitis in early 2023. LYT-500 is an orally administered combination of therapeutic agents in development for IBD. We expect preclinical proof-of-concept data for LYT-500 in the first half of 2022."

New trial • Preclinical • Immunology • Inflammatory Bowel Disease

PureTech Health plc – Half-Year Report (Businesswire) - "PureTech expects preclinical proof-of-concept data for LYT-500 in the first half of 2022. LYT-500 contains a unique combination of IL-22 and an anti-inflammatory drug, which is designed to address the two key underlying causes of IBD pathogenesis and progression, namely mucosal barrier disruption and inflammation."

Preclinical • Immunology • Inflammatory Bowel Disease

PureTech Acquires Remaining Interest in Founded Entity Alivio Therapeutics (Businesswire) - "PureTech Health plc...announced the acquisition of the remaining 22 percent of shares outstanding in its Founded Entity, Alivio Therapeutics ('Alivio'). Alivio’s therapeutic candidates, in development for inflammatory disorders including inflammatory bowel disease (IBD), will be integrated into the Company’s Wholly Owned Pipeline...The Wholly Owned Pipeline will include the addition of LYT-500, an orally-administered therapeutic candidate in development for the treatment of IBD."

M&A • Inflammatory Bowel Disease